NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/

Source

Previous articlePT448 – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy
Next articleIntroducing the Psychedelic News Feed